CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $8.10 ($115,726)
- 4 Open-market sale President and CEO sold 1,010 shares at $9.01 ($9,099)
- 4 Open-market sale President and CEO sold 32,336 shares at an average $9.12 ($295,065)
- 4 Open-market sale President and CEO sold 26,056 shares at an average $9.15 ($238,291)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale President and CEO sold 64,967 shares at an average $9.16 ($595,045)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale President and CEO sold 85,536 shares at an average $9.28 ($793,907)
- 4 Exercise or conversion Chief Technology Officer & EVP acquired 5,000 shares (option exercise)
- 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $8.57 ($122,325)
- 4 Open-market sale President and CEO sold 233 shares at $9.00 ($2,097)
- 4 Open-market sale Chief Technology Officer & EVP sold 14,279 shares at $7.58 ($108,266)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Aunins John G. sold 1,738 shares at $11.02 ($19,153)
Page 14 of 19 · 380 filings